Serum HER-2: A new biomarker?;sHER-2 : un nouveau marqueur ?

Medecine Nucleaire

Volumn 34, Issue 1, 2010, Pages 66-71

  Tse, C ^a  

^a HÔPITAL TENON   (France)

Author keywords

Breast cancer; ERBB2; Extracellular domain; HER 2; P105HER 2

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; LETROZOLE; PROTEIN P105; TRASTUZUMAB;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RELAPSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SPACE; HUMAN; IMMUNOASSAY; METASTASIS; PATHOPHYSIOLOGY; PATIENT MONITORING; PRACTICE GUIDELINE; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REFERENCE VALUE; SHORT SURVEY; TREATMENT RESPONSE;

EID: 74749104850     PISSN: 09281258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mednuc.2009.11.010     Document Type: Short Survey

References (37)

1. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1998) 177-182
2. Ferretti G., Felici A., Papaldo P., Fabi A., and Cognetti F. HER-2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol 19 (2007) 56-62
3. Sauter G., Lee J., Barlett J.M.S., Slamon D.J., and Press M.F. Guidelines for Human Epidermal Growth Factor Receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27 (2009) 1323-1333
4. Wolff A.C., Hammond E.H., Schwartz J.N., Hagerty K.L., Craig Allred H.D., Cote R.J., et al. American Society of Clinical Oncology/College of American Pathologists guidelines recommendations for Human Growth Factor Receptor 2 testing in breast cancer. J Clin Oncol 25 (2007) 118-145
5. Perez E.A., Suman V.J., Davidson N.E., Martino S., Kaufman P.A., Lingle W.L., et al. HER2 testing by local, central and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol 24 (2006) 3032-3038
6. Carney W., Neumann R., Lipton A., Leitzel K., Ali S.M., and Price C.P. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem 49 (2003) 1579-1598
7. Leary A.F., Hanna W.M., Van de Vijver M.J., Penault-Llorca F., Rüschoff J., Osamura R.Y., et al. Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. J Clin Oncol 27 (2009) 1694-1705
8. Burgess A.W., Cho H.S., Eigenbrot C., Ferguson K.M., Garett T.P.J., Leahy D.J., et al. An open and shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12 (2003) 541-552
9. Yarden Y., and Sliwlowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2 (2001) 217-237
10. Citri A., and Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7 (2006) 505-516
11. Singer C.F., Köstler W., and Hudelist G. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies. Biochim Biophys Acta Rev Cancer 1786 (2008) 105-113
12. Meden H., Mielke S., Schauer A., and Kuhn W. Serum levels of the c-erbB-2 (HER2/neu) encoded oncoprotein fragment p105 in normal pregnancies. In Vivo 11 (1997) 51-54
13. Tse C., Lefevre G., Berkane N., Flahault A., Toumi K., Brault D., et al. Increased serum maternal levels of the HER2 oncoprotein p105 ectodomain in preeclampsia. Clin Chem Lab Med 42 (2004) 142-146
14. Molina R., Jo J., Filelle X., Bruix J., Castells A., Hague M., et al. Serum levels of c-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases. Tumour Biol 8 (1997) 88-96
15. Perik P.J., De Vries E.G., Gietema J.A., Van Der Graaf W.T.A., Smilde T.D.J., Sleifer D.T., et al. Serum HER2 levels are increased in patients with chronic heart failure. Eur J Heart Fail 9 (2007) 173-177
16. Stieber P. HER-2/neu serum level as a tumor marker in patients with breast cancer. XII International Symposium on biology and clinical usefulness of tumor markers (Barcelone); 2009; communication orale.
17. Dresse M., Mayr D., Heinemann V., Kahlert S., Bauerfeind D., Nagel D., et al. HER-2/neu in tissue and serum at time of primary diagnosis of breast cancer. J Clin Oncol 27 (2009) e11500 [abstract]
18. Meng S., Tripathy D., Shete S., Ashfaq R., Haley B., Perkins S., et al. HER-2 gene amplification can be acquired as breast cancer progress. PNAS 101 (2004) 9393-9398
19. Zidan J., Dashkovsky I., Stayerman C., Basher W., Cozakov C., and Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 93 (2005) 552-556
20. Cho E.Y., Han J.J., Choi Y.L., Kim K.M., and Oh Y.L. Comparison of HER-2 EGFR and cyclin D1 in primary breast cancer and paired metastatic lymph nodes: an immunohistochemical and chromogenic in situ hybridization study. J Korean Med Sci 23 (2008) 1053-1061
21. Santinelli A., Pisa E., Stramazzotti D., and Fabris G. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer 122 (2008) 999-1004
22. Lower E.E., Glass E., Blau R., and Harman S. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 113 (2009) 301-306
23. Tse C., Brault D., Gligorov J., Antoine M., Neumann R., Lotz J.P., et al. Evaluation of the quantitative analytical methods real-time PCR for the HER-2 gene quantification and ELISA of serum HER-2 protein and comparison with fluorescence in situ hybridization and immunohistochemistry for determining HER-2 status in breast cancer patients. Clin Chem 51 (2005) 1093-1101
24. Kong S.Y., Nam B.H., Lee K.S., Kwon Y., Lee E.S., Seong M.V., et al. Predicting tissue HER-2 status using serum HER-2 levels in patients with metastatic breast cancer. Clin Chem 52 (2006) 1510-1515
25. Harris L., Fritsche H., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 33 (2007) 5287-5294
26. Namer M., Gligorov J., Luporsi E., Serin D., et al. Cancers du sein : recommandations pour la pratique clinique de Saint-Paul-de-Vence. Oncologie 9 (2007) 593-644
27. Carney W.P. Hidden HER-2/neu-positive breast cancer: how to maximize detection. IDrugs 12 (2009) 238-242
28. Esteva F.J., Cheli C.D., Fritsche H., Fornier M., Slamon D., Thiel R.P., et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 7 (2005) R436-443
29. Ali S.M., Carney W.P., Esteva F.J., Fornier M., Harris L., Köstler W.J., et al. Serum human epidermal growth factor receptor 2 proto-oncogene and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer 113 (2008) 1294-1301
30. Köstler W.J., Schwab B., Singer C.F., Neumann R., Rücklinger E., Brodowicz T., et al. Monitoring of serum HER-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 10 (2004) 1618-1624
31. Colomer R., Llombart-Cussac A., Lloveras B., Ramos M., Mayordomo J.I., Fernandez R., et al. High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study. Cancer 110 (2007) 2178-2185
32. Schippinger W., Dandachi N., Regitnig P., Hofmann G., Balic M., Neumann R., et al. The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer. Am J Clin Pathol 128 (2007) 630-637
33. Saghatchian M., Guepratte S., Hacene K., Neumann R., Floiras J.L., and Pichon M.F. Serum HER-2 extracellular domain: relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients. Int J Biol Markers 19 (2004) 14-22
34. Sorensen P.D., Jakobsen E.H., Langkjer S.T., Bokmand S., Ostergaard B., Olsen D.A., et al. Serum HER-2 concentrations for monitoring women with breast cancer in a routine oncology setting. Clin Chem Lab Med 47 (2009) 1117-1123
35. Schippinger W., Regitnig P., Bauernhofer T., Ploner F., Hofmann G., Krippl P., et al. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer. Oncol Rep 11 (2004) 131-136
36. Ali S.M., Leitzel K., Chinchilli V.M., Engle L., Demers L., Harvey H.A., et al. Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin Chem 48 (2002) 1314-1320
37. Bramwell V.H.C., Doig G.S., Tuck A.B., Wilson S.M., Tonkin K.S., Tomiak A., et al. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer. Breast Cancer Res Treat 114 (2009) 503-511